Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients

Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients

ObjectiveTo estimate the cost-effectiveness of adding serplulimab to chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC) patients in a first-line setting from a Chinese perspective.MethodsA three-health state partitioned survival model was constructed to simulate disease developm...

Full description

Bibliographic Details
Main Authors: Hanrui Zheng, Ya Zeng, Feng Wen, Ming Hu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Immunology
Subjects:
cost-effectiveness
serplulimab
chemotherapy
squamous non-small cell lung cancer
partitioned survival model
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1382088/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1382088/full

Similar Items